| Literature DB >> 31015839 |
Ngan Nguyen1, Manjari Pandey2,3.
Abstract
BACKGROUND: Brown recluse spider (BRS) envenomation can lead to significant morbidity through severe local reaction and systemic illness including acute hemolytic anemia, rhabdomyolysis, disseminated intravascular coagulopathy (DIC), and even death. We aim to describe the clinical features and the roles of antibiotics and steroids in the treatment of loxoscelism.Entities:
Year: 2019 PMID: 31015839 PMCID: PMC6446102 DOI: 10.1155/2019/4091278
Source DB: PubMed Journal: Adv Hematol
Admission data and patient characteristics.
| Admission data and patient characteristics | |
|---|---|
| Incidence Rate; % (n) | |
|
| |
| Age in years (median, range) | 30,18-53 |
|
| |
| Gender | |
|
| |
| Male | 11.1% (1) |
|
| |
| Female | 89.9% (8) |
|
| |
| Antecedent spider bite documented | |
|
| |
| Yes | 67.7% (6) |
|
| |
| No | 33.3% (3) |
|
| |
| Bite location | |
|
| |
| Distal upper extremity | 33.3% (3) |
|
| |
| Proximal upper extremity | 11.1% (1) |
|
| |
| Proximal lower extremity | 55.6% (5) |
|
| |
| Admission type | |
|
| |
| General Med-Surg | 55.6% (5) |
|
| |
| ICU | 45.4% (4) |
|
| |
| Hospital stay length in days (mean ± SD) | 7.3 ± 2.8 |
|
| |
| Chief complaints at admission | |
|
| |
| Fever | 66.7% (6) |
|
| |
| Rash | 100% (9) |
|
| |
| Pain and swelling | 44.4% (4) |
|
| |
| Jaundice | 22.2% (2) |
Figure 1Recluse spider bite with skin necrosis. (a), (b): area of ecchymosis (a) and black eschar (b) after recluse spider bite. (c) Black eschar surrounded by miliary rash as a result of recluse spider bite local reaction.
Figure 2Peripheral blood smears in patients with hemolytic anemia: peripheral smear showed microspherocytes and some increased bands.
Clinical findings and associated treatments.
| Clinical findings | Percentage (n) of patients |
|---|---|
| Skin necrosis | 44.4% (4) |
| Sepsis | 66.7% (6) |
| Fever | 66.7% (6) |
| Tachycardia | 77.8% (7) |
| Hypotension | 66.7% (6) |
| Hemolytic anemia | 100% (9) |
| Acute kidney injury | 33.3% (3) |
| Transaminitis | 55.6% (5) |
Laboratory and clinical course of patients with systemic loxoscelism.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | |
|---|---|---|---|---|---|---|---|---|---|
| Initial WBC count (x103/mL) | 5.6 | 40.7 | 17.1 | 44.8 | 14 | 11.4 | 13 | 9.3 | 9.3 |
| Peak WBC count (x103/mL) | 15.9 | 50.9 | 65 | 44.8 | 17.3 | 29.4 | 16 | 50.2 | 13.4 |
| Lowest platelet (x103/mL) | 136 | 365 | 152 | 179 | 136 | 124 | 117 | 144 | 320 |
| Initial Hgb (g/dL) | 10.1 | 5.3 | 3.5 | 11.7 | 4.7 | 12 | 8.8 | 9.3 | 14.2 |
| Lowest Hgb (g/dL) | 6.3 | 5.3 | 3.5 | 8.2 | 4.7 | 4.4 | 6.0 | 7.6 | 4.8 |
| Onset of hemolysis relative to bite (days) | 5 | 3 | 4 | 5 | 3 | 7 | 6 | 1 | 6 |
| Hgb at discharge (g/dL) | 7.5 | 8.2 | 8.8 | 9.1 | 11.1 | 6.9 | 7.8 | 12 | 9.1 |
| Peak Reticulocyte count (%) | 3.9 | 10.8 | 0.6 | 3.93 | 1.6 | 2.6 | 2.7 | 10.5 | 13.2 |
| Haptoglobin (mg/dL) | <8 | <8 | Not measured | Not measured | Not measured | 67 | Not measured | 158 | 197 |
| Peak total bilirubin | 16.2 | 5.2 | 39.2 | 0.5 | 4.3 | 4.3 | 2.4 | 21 | 5.6 |
| LDH at admission (U/L) | 1146 | 953 | 2337 | 328 | 1633 | 320 | 261 | 566 | 549 |
| DAT (Surface IgG) | negative | negative | positive | negative | negative | positive | negative | positive | positive |
| DAT (Surface C3) | negative | negative | positive | negative | negative | positive | negative | positive | positive |
| Hospital admission | Med-Surg | ICU | ICU | ICU | Med-Surg | Med-Surg | ICU | Med-Surg | Med-Surg |
| Transfusion (pRBC units) | 1 | 3 | 4 | 0 | 7 | 3 | 3 | 2 | 2 |
| Corticosteroid use | No | No | Yes | Yes | No | No | No | Yes | Yes |
| IVIg use | No | No | No | No | No | No | No | No | Yes |
| Incision and drainage | No | Yes | No | No | No | Yes | Yes | Yes | No |
Abbreviations: WBC, White Blood Cell; LDH, Lactate Dehydrogenase; DAT, Direct Antiglobulin Test; pRBCs, packed Red Blood Cells.